International Society for Extracellular Vesicles and International Society for Cell and Gene Therapy statement on extracellular vesicles from mesenchymal stromal cells and other cells: considerations for potential therapeutic agents to suppress coronavirus disease-19
Verena Börger, Daniel J. Weiss, Johnathon D. Anderson, Francesc E. Borràs, Benedetta Bussolati, David R. F. Carter, Massimo Dominici, Juan Manuel Falcón‐Pérez, Mario Gimona, Andrew F. Hill, Andrew M. Hoffman, Dominique P.V. de Kleijn, Bruce L. Levine, Rebecca Lim, Jan Lötvall, S. Alex Mitsialis, Marta Tortajada, Maurizio Muraca, Rienk Nieuwland, Anna Nowocin, Lorraine O’Driscoll, Luis A. Ortiz, Donald G. Phinney, Ilona Reischl, Eva Rohde, Ralf Sanzenbacher, Clotilde Théry, Wei Seong Toh, Kenneth W. Witwer, Sai Kiang Lim, Bernd Giebel
Abstract
STATEMENT: The International Society for Cellular and Gene Therapies (ISCT) and the International Society for Extracellular Vesicles (ISEV) recognize the potential of extracellular vesicles (EVs, including exosomes) from mesenchymal stromal cells (MSCs) and possibly other cell sources as treatments for COVID-19. Research and trials in this area are encouraged. However, ISEV and ISCT do not currently endorse the use of EVs or exosomes for any purpose in COVID-19, including but not limited to reducing cytokine storm, exerting regenerative effects or delivering drugs, pending the generation of appropriate manufacturing and quality control provisions, pre-clinical safety and efficacy data, rational clinical trial design and proper regulatory oversight.